This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Galectin Therapeutics Hosted International Conference On Galectins And Disease

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the proceedings of an international galectin meeting, hosted by Galectin Therapeutics and held at the Harvard Club in Boston, MA, on September 17-19, has been accepted for publication by the American Chemical Society. The book, entitled “Galectins and Disease: Implications for Targeted Therapeutics”, is expected to be published in early 2013 and is edited by Dr. Anatole A. Klyosov, Chief Scientist and Founder, and Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer, both of Galectin Therapeutics.

“Presentations by international experts in galectin biology and disease confirmed the critical importance of galectin proteins in organ fibrosis and cancer,” said Dr. Traber. “We are pleased that our preclinical data and development programs in liver fibrosis and melanoma were well represented and received by the scientists at the meeting. It was broadly agreed by the participants that this decade will herald the realization of galectin-targeted therapeutics in multiple diseases.”

“In addition to the importance in cancer, the critical role of galectin-3 protein in fibrosis of multiple organs was emphasized, including liver, lung, kidney and heart,” said Dr. Traber. “In fact, one of the speakers indicated that fibrosis of these organs, the ultimate cause of organ failure, accounts for 45% of all mortality in the United States.”

The two and a half day meeting featured 50 participants and 29 presentations by experts from across the United States, Europe and Latin America. The book will include 26 chapters that cover galectin structure and basic biology, galectin mechanisms and therapeutic approaches in cancer, and the mechanisms and therapeutic approaches in inflammation and fibrosis. The focus of the presentations and discussions was how to effectively move the strong basic science in galectins into clinical trials in important human diseases.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs